In biopharma, patents are everything. In tech? Not so much.
Which is why it was unusual to see a company that’s trying to turn software into medicine announce this week that it’s bagged several patents.
Boston-based Akili Interactive Labs’s new patents, issued in the U.S. and Japan, are meant to deter competitors from copying the algorithms underlying the video games it’s developing to try to treat conditions like ADHD, depression, and multiple sclerosis.
About the Author Reprints
